Healthcare Industry Updates’ Post

Breaking Boundaries in Healthcare: The Cardiac Tissue Engineering Revolution 🚀 Download PDF Brochure: https://lnkd.in/dSjg8ACc The global cardiac tissue engineering market is poised for transformative growth, driven by groundbreaking innovations that are reshaping cardiovascular treatment approaches. Key Market Insights: 📊 Market Segmentation: - Materials: Advanced scaffolds and cutting-edge stem cell technologies - Products: Innovative heart valves and vascular grafts - Applications: Addressing myocardial infarction and congenital heart diseases - End-Users: Hospitals, clinics, academic institutions, and research centers 🔬 Market Drivers Propelling Innovation: - Escalating prevalence of cardiovascular diseases worldwide - Robust support from leading market players and government initiatives - Surging demand for regenerative medicine solutions - Breakthrough advancements in 3D bioprinting technologies 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Terumo Medical Corporation, Artivion, Inc., Baxter International Inc., Teijin Limited, Medtronic, Boston Scientific, Abbott, Merck KGaA, Darmstadt, Germany, Elutia, W. L. Gore & Associates, Meril, FUJIFILM Holdings Corporation, Vascudyne Inc, BICO, REPROCELL, PromoCell, Axol Bioscience Ltd., BPS Bioscience Inc., Cell Application, Inc. (US), Viscofan DE GmbH #HealthTech #MedicalInnovation #CardiacResearch #RegenerativeMedicine #BiomedicalEngineering

𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐭𝐡𝐞 𝐒𝐲𝐧𝐭𝐡𝐞𝐬𝐢𝐬 𝐌𝐨𝐝𝐮𝐥𝐞𝐬 𝐟𝐨𝐫 𝐑𝐚𝐝𝐢𝐨𝐭𝐫𝐚𝐜𝐞𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/dsxuKikd As molecular imaging continues to grow in significance, synthesis modules for radiotracers are playing an increasingly pivotal role in the advancement of diagnostic imaging and therapeutic procedures, particularly in oncology, cardiology, and neurology. These automated systems are transforming the way we produce radiopharmaceuticals by offering: ➤ Efficiency: Streamlined production processes that ensure rapid synthesis of radiotracers. ➤ Precision: High reliability in delivering consistent, high-purity compounds critical for PET and SPECT scans. ➤ Safety: Reduced radiation exposure to operators with closed-system designs. 🏥 With the rise in cancer diagnosis, neurodegenerative diseases, and precision medicine, the demand for advanced synthesis modules is on the rise. Companies are investing heavily in R&D to develop cutting-edge systems that integrate automation, reduce human error, and meet stringent regulatory standards. 💼 The market is poised for exponential growth, and stakeholders—pharmaceutical companies, research institutes, and healthcare providers—are actively seeking collaborations to improve diagnostic accuracy and patient outcomes. The future of radiotracers is not just in developing new isotopes, but in innovating the technology that manufactures them efficiently. 🚀 What’s your perspective on the evolving synthesis modules market? How do you see this impacting molecular imaging in the next 5 years? The Major players are GE HealthCare, Siemens Healthineers, Philips, Eckert & Ziegler SE, iThemba LABS, Trasis, Advanced Cyclotron Systems Inc., Nordion and other players #RadiotracerSynthesis #RadiotracerProduction #SynthesisModules #PETRadiochemistry #Radiopharmaceuticals #RadiochemistryAutomation #ImagingAgents #TracerSynthesis #NuclearImaging #RadiotracerDevelopment #PositronEmissionTomography #RadiopharmaceuticalInnovation #RadiotracerResearch #Radionuclide

Preclinical Imaging Market: A Global Perspective 🌐 📥 Download Complete PDF: https://lnkd.in/dtjxaqZa The preclinical imaging market is expected to grow significantly, reaching an estimated USD 5,101 million by 2029 from USD 3,997 million in 2024, with a CAGR of 5.0%. 📈 This growth is driven by advancements across product types like Optical Imaging (Bioluminescence), PET, SPECT, and MRI—technologies essential in early-stage drug discovery and research. In addition, innovations in optical imaging reagents (e.g., infrared dyes) and specialized software are enhancing research capabilities, supporting new breakthroughs in both oncology and neurology. Key stakeholders such as pharmaceutical companies and imaging centers are increasingly investing in these tools to accelerate the development of new therapeutics. 🌍 The market growth is anticipated globally, with notable regional expansions as demand for precision medicine and tailored treatments rises. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Bruker Bruker BioSpin Revvity MR SOLUTIONS Mediso Medical Imaging Systems TriFoil Imaging FUJIFILM VisualSonics, Inc. MILabs Aspect Imaging LI-COR BIOSCIENCES UK LIMITED ICONEUS ADVANCED MOLECULAR VISION LIMITED IVIM Technology Cubresa Inc. Berthold Technologies SOFIE Medlink Imaging, a Vieworks Company AI4R KUBTEC Medical Imaging MEDIKORS INC. Miltenyi Biotec #PreclinicalImaging #HealthcareInnovation #DrugDevelopment #Oncology #Neurology #GlobalMarket #ImagingSolutions #Pharma

𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐮𝐦𝐚𝐧 𝐎𝐬𝐭𝐞𝐨𝐛𝐥𝐚𝐬𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝟐𝟎𝟑𝟒 ▶𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/giJBwCjm Human osteoblasts are specialized cells crucial for bone formation, originating from mesenchymal stem cells and playing a vital role in the development, maintenance, and repair of the skeletal system. They synthesize bone matrix and facilitate bone mineralization, helping maintain bone density and structure. This report offers a comprehensive analysis of the global Human Osteoblasts market, providing both quantitative and qualitative insights by company, region, type, and application. It explores market competition, supply and demand trends, and key factors driving demand across various markets. The report also includes company profiles, product examples, and market share estimates for selected leaders in 2024. 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: ▶𝐁𝐲 𝐓𝐲𝐩𝐞: Human Cell Culture, Osteoblast Cell Lines. ▶𝐁𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧: Hospitals, Specialty Clinics, Ambulatory Surgical Centers. ▶𝐆𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐲: North America, Europe, APAC, Latin America, and Middle East & Africa. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐜𝐨𝐯𝐞𝐫𝐞𝐝:                     Sigma-Aldrich, Athersys., Cerapedics Inc., Cryolife Inc, Cytori Therapeutics Inc, U.S. Stem Cell, Inc, Vericel® Corporation, Wright Medical, Biocomposites, BD, Zimmer Biomet, PromoCell. #GlobalHumanOsteoblasts #OsteoblastsMarket #BoneRegeneration #TissueEngineering #StemCellResearch #BoneHealthInnovation #OrthopedicResearch #fatposglobal

Congratulations to convEyXO on being the latest addition to the "Global Database of Exosome Companies, 2024": https://lnkd.in/ezHg2Pc ConvEyXO, a Belgian biotech company, targets inflammatory and degenerative diseases with unmet medical needs by reducing inflammation and repairing tissue damages from cellular senescence with its Therapeutic Platform based on small Extracellular Vesicles (sEV or exosomes) secreted by Mesenchymal Stem Cells (MSCs), with their intrinsic immuno-modulatory and regenerative properties, amplified by loaded miRNA. ConvEyXO resolves sEV industrialization key challenges with a proprietary Technology Platform, making their therapies triple A with (1) homogenous industrial manufacturing from single cell line sourcing, with robust isolation, purification and characterization processes, (2) cost-efficient scalable production with patented process and proprietary 3D custom fixed-bed bioreactor and (3) Amplified sEV native properties by loading miRNA with a breakthrough microfluidic technology. #exosomes #extracellularvesicles #advancedtherapies Frédéric Tonglet

Congratulations to convEyXO on being the latest addition to the "Global Database of Exosome Companies, 2024": https://lnkd.in/g8VVNaHr ConvEyXO, a Belgian biotech company, targets inflammatory and degenerative diseases with unmet medical needs by reducing inflammation and repairing tissue damages from cellular senescence with its Therapeutic Platform based on small Extracellular Vesicles (sEV or exosomes) secreted by Mesenchymal Stem Cells (MSCs), with their intrinsic immuno-modulatory and regenerative properties, amplified by loaded miRNA. ConvEyXO resolves sEV industrialization key challenges with a proprietary Technology Platform, making their therapies triple A with (1) homogenous industrial manufacturing from single cell line sourcing, with robust isolation, purification and characterization processes, (2) cost-efficient scalable production with patented process and proprietary 3D custom fixed-bed bioreactor and (3) Amplified sEV native properties by loading miRNA with a breakthrough microfluidic technology. #exosomes #extracellularvesicles #advancedtherapies Frédéric Tonglet

Are you looking to leverage the advantages of Exosome application, from discovery, to manufacturing, to commercialization? Then look no further than Exosomes Europe, the go-to event for anyone looking to advance their EV research. 📍 DoubleTree Tower of London 💻 Sessions available digitally 📅 5-6 of June 💲 Buy Two Passes, Get One Free* 🌐 Book Now: https://bit.ly/49xSPGV Hear from Founder & CEO of Mursla Bio, Pierre Arsène as he discusses the quest for the 'killer application' of EV products, and answers all your burning questions such as:   🔻 Why hasn't the first 'Killer Application' in EV modality emerged yet? 🔻 What could be missing on the path towards that? 🔻 Which applications are leading the way in Therapeutics, Diagnostics and beyond. 🔻 What are the future perspectives and emerging directions in the EV space? PLUS, we'll help you on the path to exosome success, with in-depth case studies and innovative new data on using EVs for regenerative medicine, skin rejuvenation, cancer treatments, cell-specific cargo delivery & vaccines, genetic therapies, spinal cord injuries, orthopedics and more!   You're spoilt for choice, so book now & don't miss out on hearing direct from those on the front lines of exosome research! PLUS, we're now offering buy two get one free*, so you can upscale the whole team for less! Learn More: https://bit.ly/3T8Pwif *T&Cs on website #Exosomes #ExosomesEurope #ApplicationsOfExosomes #extracellularvesicles #biopharma #pharma #bioprocessing #bioprocess #bioprocessinternational #hybrid #hybridevent #informa #informaconnect

Encapsulating Life: Navigating the Live Cell Encapsulation Market Get To More: https://lnkd.in/gn9WmaNU Unlocking Potential: The Live Cell Encapsulation Market represents a #frontier of innovation in #biotechnology, offering transformative #solutions for cell therapy and regenerative medicine. Live cell #encapsulation involves the #immobilization of living cells within protective matrices, enabling their #transplantation into the body for therapeutic purposes. This technology holds immense promise for treating a wide range of diseases, including diabetes, #Parkinson's disease, and cancer, by providing a #controlled #microenvironment for sustained cell survival and function. Market Dynamics: The Live Cell Encapsulation Market is driven by a confluence of factors, including the #growing prevalence of chronic diseases, advancements in #biocompatible #materials, and increasing investment in cell-based therapies. As researchers continue to explore the potential of live cell #encapsulation in tissue #engineering, drug delivery, and cell transplantation, the market is witnessing rapid #expansion. Moreover, collaborations between academia, industry, and regulatory bodies are facilitating the #development and #commercialization of innovative encapsulation #technologies, driving market #growth and #adoption. Future Outlook: With ongoing #research and #development efforts, the future outlook for the Live Cell Encapsulation Market is highly #promising. Emerging trends such as 3D cell #printing, #microfluidics, and bioengineering hold the potential to revolutionize the field, enabling precise control over cell encapsulation# processes and #enhancing therapeutic outcomes. Furthermore, as regulatory pathways for cell-based therapies become more #defined and #standardized, the market is expected to witness increased #commercialization and widespread clinical adoption of live cell #encapsulation technologies, paving the way for novel treatments and improved patient outcomes. Key players in the Live Cell Encapsulation Market: • Austrianova (United States) • Sernova Corp. (Canada) • Thermo Fisher Scientific Inc. (United States) • Balchem Corporation (United States) • Blackstone Labs (United States) #LiveCellEncapsulation #Biotechnology #CellTherapy #RegenerativeMedicine #TissueEngineering #DrugDelivery #ChronicDiseases #DiabetesTreatment #ParkinsonsTreatment #CancerTherapy #BiocompatibleMaterials #3DCellPrinting #Microfluidics #Bioengineering #ClinicalResearch

𝐋𝐈𝐅𝐓𝐎𝐒𝐂𝐎𝐏𝐄: 𝐀𝐈-𝐜𝐨𝐧𝐭𝐫𝐨𝐥𝐥𝐞𝐝, 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐜𝐞𝐥𝐥 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 Together with the Fraunhofer-Institut für Produktionstechnologie IPT, the Fraunhofer ILT has developed a new AI-supported high-throughput process for fully automated cell selection. The LIFTOSCOPE localizes, identifies and measures dozens of living cells per second and transfers them to microtiter plates using laser-induced forward transfer (LIFT). This technology opens up significant advances in personalized medicine, pharmaceutical and clinical research. The innovative process not only enables the efficient isolation of pluripotent stem cells, but also high-producer and immune cells. The use of AI and lasers in this fully automated process promises maximum throughput and survival rates of over 90 percent. Learn more about this exciting technology in our video. #CellTherapy #Innovation #Fraunhofer #LIFTOSCOPE #fraunhoferilt #biofacbrication #medicaltechnology #personalizedmedicine #FutureofMedicine #lasertechnology #photonics #photonicsinaachen